1246532-45-5

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 39639-45-7 (2-chloro-9H-purin-6-yl)-cyclohexyl-amine 
• 108-91-8 cyclohexylamine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 1246532-46-6 N₆-cyclohexyl-N₂-(2-methyl-4-morpholin-4-yl-phenyl)-9-(tetrahydropyran-2-yl)-9H-purine-2,6-diamine 
• 1246532-48-8 {4-[6-cyclohexylamino-9-(tetrahydro-pyran-2-yl)-9H-purin-2-ylamino]-3-methyl-phenyl}-(4-methyl-piperazin-1-yl)-methanone 
• 1246532-97-7 C₃₂H₄₆N₈O₄ 
• 1395171-89-7 C₃₂H₄₆N₈O₃ 
• 1395171-07-9 C₃₁H₄₃N₇O₄ 
• 1310346-84-9 methyl 1-[4-[[6-(cyclohexylamino)-9-tetrahydropyran-2-yl-purin-2-yl]amino]-3-methoxy-phenyl]piperidine-4-carboxylate 
• 1246532-06-8 N₆-cyclohexyl-N₂-[4-(morpholin-4-yl)-2-(trifluoromethoxy)phenyl]-9H-purine-2,6-diamine 
• 1395171-83-1 C₂₇H₃₄F₃N₇O₃ 
• 1383810-47-6 C₂₂H₂₉N₇O₃S 
• 1395171-78-4 C₂₇H₃₇N₇O₄S 
• 1383810-49-8 C₂₂H₂₉N₇OS 
• 1395171-74-0 C₂₇H₃₇N₇O₂S 
• 1246529-73-6 N₆-cyclohexyl-N₂-[2-ethoxy-4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine 
• 1395171-63-7 C₂₈H₃₉N₇O₃ 

Relevant academic research and scientific papers

Synthesis and evaluation of 18F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression

Type II topoisomerase (Topo-II) is an ATP-dependent enzyme that is essential in the transcription, replication, and chromosome segregation processes and, as such, represents an attractive target for cancer therapy. Numerous studies indicate that the respo

HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl k

Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Efforts to optimize biological activity, novelty, selectivity and oral bioavailability of Mps1 inhibitors, from a purine based lead MPI-0479605, are described in this Letter. Mps1 biochemical activity and cytotoxicity in HCT-116 cell line were improved. On-target activity confirmation via mechanism based G2/M escape assay was demonstrated. Physico-chemical and ADME properties were optimized to improve oral bioavailability in mouse.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.